Skip to content
lifestyle.claritypointe.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Odyssey Therapeutics Inc
Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
October 12, 2026
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
October 6, 2026
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
September 16, 2026
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
August 26, 2026
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4, 2026
Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
May 21, 2026